GLPG2222, an investigational cystic fibrosis transmembrane conductance (CFTR) corrector candidate from Galapagos NV, achieved its primary endpoint of improved lung function in a phase II study.
The phase II ALBATROSS study evaluated two once-daily doses – 150 mg and 300 mg – of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s CF drug, Kalydeco. Treatment with Kalydeco was continued during the course of the study.
The study achieved its primary objective of safety and was well tolerated in the patient population. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study.
